Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1995;26:1431-1437

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimura, H.
Right arrow Articles by Tomonaga, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimura, H.
Right arrow Articles by Tomonaga, M.

(Stroke. 1995;26:1431-1437.)
© 1995 American Heart Association, Inc.


Articles

Circulation of Red Blood Cells Having High Levels of 2,3-Bisphosphoglycerate Protects Rat Brain From Ischemic Metabolic Changes During Hemodilution

Hideo Kimura; Naotaka Hamasaki; Masaaki Yamamoto Masamichi Tomonaga

From the Department of Neurosurgery, Fukuoka University School of Medicine, and Department of Clinical Chemistry and Laboratory Medicine (N.H.), Kyushu University Faculty of Medicine, Fukuoka, Japan.

Background and Purpose We designed the present study to examine the effects of red blood cell oxygen-delivering capacity on ischemic brain metabolism during hemodilution with respect to red blood cell 2,3-bisphosphoglycerate content.

Methods A modification of red blood cell 2,3-bisphosphoglycerate content was achieved by an exchange transfusion of blood in which red blood cells were treated with either phospho(enol)pyruvate or inorganic phosphate in spontaneously hypertensive rats. Hematocrit values of circulating blood were varied from 30% to 20% during transfusion. Brain ischemia was produced in rats by bilateral carotid artery occlusion lasting 60 minutes. The concentrations of ATP and 2,3-bisphosphoglycerate in the blood and the ATP, phosphocreatine, and lactate concentrations in the brain were estimated by an enzymatic method.

Results Red blood cell 2,3-bisphosphoglycerate concentration increased to 200% of the pretransfusion level after the transfusion in which red blood cells were treated with phospho(enol)pyruvate, whereas the concentration decreased to 80% after the transfusion in which red blood cells were treated with phosphate. Red blood cell ATP content did not differ significantly between the phospho(enol)pyruvate- and phosphate-treated groups after transfusion. When hematocrit was approximately 30%, the ischemic brain ATP and lactate contents did not differ between the nonischemic and ischemic groups. However, as hematocrit was reduced to less than 25% the ischemic brain ATP content remarkably decreased and the lactate content substantially increased in the 2,3-bisphosphoglycerate–subnormal red blood cell group. In contrast, the ischemic brain ATP and phosphocreatine contents in the 2,3-bisphosphoglycerate–enriched red blood cell group were preserved and as high as those in the nonischemic group under the same conditions.

Conclusions Cerebral ischemia was compensated with the increment of cerebral blood flow as a result of the reduction of hematocrit to optimal levels, but the extreme hemodilution induced insufficient oxygen supply to the brain tissue, resulting in a more marked impairment of brain metabolism despite an increase in cerebral blood flow. However, even in extreme hemodilution conditions the 2,3-bisphosphoglycerate–enriched red blood cells in circulating blood protected the brain from ischemic metabolic changes. These results suggest that the 2,3-bisphosphoglycerate–enriched red blood cells in the circulating blood may thus compensate for the insufficient oxygen supply in extremely anemic conditions by providing a sufficient supply of oxygen in the face of ischemic insult.


Key Words: 2,3 biphosphoglycerate • rats • cerebral metabolism • hemodilution • oxygen




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. A. L. Calbet, R. Boushel, G. Radegran, H. Sondergaard, P. D. Wagner, and B. Saltin
Why is VO2 max after altitude acclimatization still reduced despite normalization of arterial O2 content?
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R304 - R316.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
O. Eichelbronner, M. D'Almeida, A. Sielenkamper, W. J. Sibbald, and I. H. Chin-Yee
Increasing P50 does not improve DO2CRIT or systemic VO2 in severe anemia
Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H92 - H101.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. P. Grocott, R. D. Bart, H. Sheng, Y. Miura, R. Steffen, R. D. Pearlstein, D. S. Warner, and E. P. Wei
Effects of a Synthetic Allosteric Modifier of Hemoglobin Oxygen Affinity on Outcome From Global Cerebral Ischemia in the Rat • Editorial Comment
Stroke, August 1, 1998; 29(8): 1650 - 1655.
[Abstract] [Full Text] [PDF]